HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically.

AbstractBACKGROUND:
Analysis of potentially prognostic relevant factors of carcinoid tumors of the lung.
METHODS:
Clinical features, tumor size, and features derived from immuno- and ligandohistochemistry, cytometry and histometry, and survival have been analyzed in 82 potentially curatively resected carcinoid tumors of the lung.
RESULTS:
Patients with typical carcinoid tumors had a longer history of symptoms (13 vs. 8 months), fewer smoked (30% vs. 80%), and developed less frequently lymph node metastases (20% vs. 65%) compared to patients with atypical carcinoids. Statistically significant differences between both cell types have been observed in cytometric and histometric features, and binding of Lewis A trisaccharide (Lea). Prognosis is associated with the cell type, presence of lymph node metastases and heparin-binding lectin (HBL), certain cytometric and structural features, and binding of macrophage migration inhibitory factor (MIF) and beta-N-acetyl-D-galactosamine (beta-GalNAc).
CONCLUSIONS:
Complete lymph node dissection is necessary, data of cytometry, histometry, and ligandohistochemistry might eventually predict the course of the disease.
AuthorsK Kayser, C Kayser, W Rahn, N V Bovin, H J Gabius
JournalJournal of surgical oncology (J Surg Oncol) Vol. 63 Issue 2 Pg. 99-106 (Oct 1996) ISSN: 0022-4790 [Print] United States
PMID8888802 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adolescent
  • Adult
  • Aged
  • Carcinoid Tumor (metabolism, pathology, surgery)
  • Female
  • Flow Cytometry
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunoenzyme Techniques
  • Immunohistochemistry
  • Lung Neoplasms (metabolism, pathology, surgery)
  • Male
  • Middle Aged
  • Prognosis
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: